P1466: EFFECT OF LUSPATERCEPT ON BONE MINERAL DENSITY IN PATIENTS WITH BETA‑THALASSEMIA ENROLLED IN THE PHASE 3 BELIEVE TRIAL
Thomas D. Coates(Children's Hospital of Los Angeles), Alì Taher(American University of Beirut Medical Center), Jeevan K. Shetty(Ente Ospedaliero Ospedali Galliera), Antonio Piga(University of Turin), Antonis Kattamis, Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Kevin H.M. Kuo(University Health Network), Yinzhi Lai(Bristol-Myers Squibb (United States)), Wen‐Ling Kuo(Chang Gung University), Sujit Sheth(Columbia University Irving Medical Center), Martina Perin(Bristol-Myers Squibb (Switzerland)), Frederik Lersch(Bristol-Myers Squibb (Switzerland))
Cited by 1
Related Papers
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
|The Lancet|2011|1.3k
Thalassaemia
|The Lancet|2017|763
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
|Haematologica|2014|389
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia
|British Journal of Haematology|2000|292